Mantle cell lymphoma is a type of cancer that occurs when the T cells of the immune system are attacked by the B cells of the blood. This can be either through a viral or bacterial attack. Ibrutinib refers to the protein of the cell that has the ability to induce a response in the B cells.
Tumors of the lungs, pancreas, liver, kidney, prostate, gallbladder, eye, esophagus and cervical cancer can develop through Ibrutinib like AZD 3759. It occurs mostly in younger adults and mostly in men. The name for this tumor is Ibrutinib-A. The exact cause is not known, but it is usually associated with deficiencies of vitamin B-12 and Fe.
When a tumor of the lymphatic system develops in these organs, the normal function of those organs is disturbed. Tumors can occur in response to a bacterial or viral infection, and they can also be a result of the normal autoimmune process. The tumors have been known to involve the bone marrow. They can also spread to other parts of the body.
Ibrutinib has shown great potential for treating lymphomas, particularly those that are large, had no response to standard therapy and grew slowly. The drug has produced favorable responses in animals and is being studied for use in humans. The drug has been approved for internal use.
It can suppress the immune system’s release of antibody-like substances called cytokines, which are supposed to attack cancer cells. These substances are normally produced by the white blood cells. However, they are inhibited by Ibrutinib and apparently not by biological inhibitors such as paclitaxel, carboplatin, efavirenz and vincristine.
Ibrutinib can reduce the size of the tumor by more than 50%. It has been shown to improve survival and to reduce tumor burden. In a recent study, patients who responded to Ibrutinib showed an improvement in their bone marrow proliferation, suggesting a possible role for the drug in reducing the risk of childhood cancers. Although additional research will need to verify these results, the early results are promising and may hold the key to a better cancer therapy and outcome.
Ibrutinib is currently undergoing clinical trials in several different part of the world. Early results from one trial in Japan have shown a trend toward a decreased incidence of childhood cancers among children taking the drug.
In a phase II trial conducted in the UK, cells from immune-compromised patients were used to test the drug’s ability to reduce cell division and kill cancer cells. Preliminary data suggest that Ibrutinib may be able to help people with immune-compromised conditions, including HIV and sickle cell disease. Contact us by clicking this link for more details.